Painful osteoarthritis: 7.5 mg/day. If necessary, the dose may be increased to 15 mg/day.
Rheumatoid arthritis: 15 mg/day. According to the therapeutic response, the dose may be reduced to 7.5 mg/day.
Ankylosing spondylitis: 15 mg/day. According to the therapeutic response, the dose may be reduced to 7.5 mg/day.
Special population: In patients with increased risks of adverse reactions, e.g. a history of gastro-intestinal disease or risk factors for cardiovascular disease, the treatment should be started at the dose of 7.5 mg/day (see Precautions).
No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 ml/min). In non-dialysed patients with severe renal impairment MOBIC is contraindicated (see Contraindications). In patients with end-stage renal failure on haemodialysis the maximum daily dose should not exceed 7.5 mg/day.
Paediatric population: As a dosage for use in children and adolescents has not yet been established, usage should be restricted to adults. There are no data for children and adolescents available in the indications painful osteoarthritis, rheumatoid arthritis or ankylosing spondylitis.
General recommendation: As the potential for adverse reactions increases with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
The total daily dosage of MOBIC should be administered as a single dose. The maximum recommended daily dose regardless of formulation is 15 mg.
MOBIC tablets and capsules are swallowed with water or other fluid in conjunction with food.
There is insufficient information on the effect of mixing crushed tablets with food or fluids.
Tablet break mark does not allow subdividing the 7.5 mg tablet into fractions of a full dose. Tablets 7.5 mg can only be subdivided for ease of swallowing.